Novartis AG
NVS
$125.57
$0.560.45%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.91B | 14.05B | 13.23B | 13.15B | 12.82B |
| Total Other Revenue | 449.00M | 782.00M | 387.00M | 405.00M | 349.00M |
| Total Revenue | 14.36B | 14.84B | 13.62B | 13.56B | 13.17B |
| Cost of Revenue | 3.54B | 3.32B | 3.22B | 3.31B | 3.23B |
| Gross Profit | 10.82B | 11.52B | 10.40B | 10.24B | 9.94B |
| SG&A Expenses | 3.30B | 3.44B | 3.06B | 3.50B | 3.13B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 70.00M | -4.00M | 148.00M | 112.00M | 778.00M |
| Total Operating Expenses | 9.77B | 9.37B | 8.80B | 9.50B | 9.54B |
| Operating Income | 4.59B | 5.46B | 4.82B | 4.06B | 3.63B |
| Income Before Tax | 4.20B | 4.53B | 4.41B | 3.29B | 3.39B |
| Income Tax Expenses | 266.00M | 507.00M | 798.00M | 465.00M | 200.00M |
| Earnings from Continuing Operations | 3.93B | 4.02B | 3.61B | 2.82B | 3.19B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.00M | 17.00M | -3.00M | -2.00M | 4.00M |
| Net Income | 3.93B | 4.04B | 3.61B | 2.82B | 3.19B |
| EBIT | 4.59B | 5.46B | 4.82B | 4.06B | 3.63B |
| EBITDA | 5.78B | 6.56B | 5.91B | 4.16B | 4.73B |
| EPS Basic | 2.04 | 2.07 | 1.83 | 1.42 | 1.59 |
| Normalized Basic EPS | 1.39 | 1.66 | 1.46 | 1.27 | 1.06 |
| EPS Diluted | 2.02 | 2.06 | 1.82 | 1.41 | 1.57 |
| Normalized Diluted EPS | 1.38 | 1.65 | 1.45 | 1.26 | 1.05 |
| Average Basic Shares Outstanding | 1.93B | 1.95B | 1.97B | 1.99B | 2.01B |
| Average Diluted Shares Outstanding | 1.94B | 1.96B | 1.98B | 2.00B | 2.03B |
| Dividend Per Share | -- | -- | -- | 3.86 | -- |
| Payout Ratio | -- | 61.49% | 147.89% | 0.00% | -- |